Sign In
Buy ALLO
$2.00
-0.0500 (-2.44%)
At Close: Jun 03, 2026
Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020
08:30am, Wednesday, 02'nd Dec 2020
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Regenerative Medicines: Universal Cell Therapy Gaining Momentum
08:03am, Tuesday, 01'st Dec 2020
Allogeneic cell therapies have a significant cost, convenience and efficiency advantage over autologous. Data from three of the leaders: Allogene, Atara and CRISPR are expected in the next 12-to-24 mo
Allogene Therapeutics' (ALLO) CEO David Chang on Q3 2020 Results - Earnings Call Transcript
02:08pm, Wednesday, 04'th Nov 2020
Allogene Therapeutics' (ALLO) CEO David Chang on Q3 2020 Results - Earnings Call Transcript
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Allogene Therapeutics Reports Third Quarter 2020 Financial Results
07:30am, Wednesday, 04'th Nov 2020
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Allogene Therapeutics to Report Third Quarter 2020 Financial Results on November 4, 2020
08:30am, Tuesday, 27'th Oct 2020
SOUTH SAN FRANCISCO, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Open d'Italia al via, Paratore e Manassero in campo - Open d'Italia
07:38am, Thursday, 22'nd Oct 2020
Seppur con 30 minuti di ritardo (rispetto a quanto inizialmente previsto), causa nebbia, è
cominciata la 77esima edizione dell'Open d'Italia di golf.
(ANSA)
Genomic Medicine: Summer 2020 Update
09:36am, Thursday, 13'th Aug 2020
FDA approvals, new guidance statements, and RMAT requests all show the pace of genomics is accelerating.
Allogene Therapeutics (NASDAQ:ALLO) Stock Rating Reaffirmed by Jefferies Financial Group
01:48am, Tuesday, 11'th Aug 2020
Allogene Therapeutics (NASDAQ:ALLO)‘s stock had its “buy” rating reissued by stock analysts at Jefferies Financial Group in a research report issued to clients and investors on Sunday, AnalystRa
Allogene Therapeutics (NASDAQ:ALLO) Rating Reiterated by Cowen
01:48am, Tuesday, 11'th Aug 2020
Allogene Therapeutics (NASDAQ:ALLO)‘s stock had its “buy” rating reiterated by analysts at Cowen in a research report issued on Sunday, AnalystRatings.com reports. Several other research firms h
Allogene's (ALLO) Q2 Loss Widens Y/Y, Pipeline Progresses
03:19pm, Thursday, 06'th Aug 2020
Allogene (ALLO) reports no revenues for the second quarter of 2020.
Allogene Therapeutics Reports Second Quarter 2020 Financial Results
11:30am, Wednesday, 05'th Aug 2020
* Initial Phase 1 Results from the ALLO-501 ALPHA Trial at ASCO Demonstrated an Overall Response Rate of 75% and Complete Response Rate of 44% in CAR T Naïve Relapsed/Refractory Non-Hodgkin Lymphoma
The Daily Biotech Pulse: Novavax Vaccine Data, Aerpio Gets $5.1M Funding For COVID Trial, Rigel Gains Big On Earnings
12:00am, Wednesday, 05'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
ABIOMED, Inc. (NASDAQ: ABMD) (FDA approved the emergency use of Abiomed's Impella heart pump in combination...
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
12:00am, Sunday, 02'nd Aug 2020
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
Vident Investment Advisory LLC Sells 18,342 Shares of Allogene Therapeutics Inc (NASDAQ:ALLO)
11:48am, Saturday, 01'st Aug 2020
Vident Investment Advisory LLC trimmed its holdings in shares of Allogene Therapeutics Inc (NASDAQ:ALLO) by 33.5% during the 2nd quarter, according to the company in its most recent 13F filing with th
